Deciphera Pharmaceuticals (DCPH) Prices 3.18M Share Common Offering at $55/Sh

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the pricing of its previously announced registered underwritten public offering of 3,181,818 shares of its common stock at a price to the public of $55.00 per share. The gross proceeds to Deciphera from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. The offering is expected to close on or about February 19, 2020, subject to customary closing conditions. In addition, Deciphera has granted the underwriters a 30-day option to purchase up to 477,272 additional shares of its common stock.

J.P. Morgan, Piper Sandler and Jefferies acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager for the offering. SunTrust Robinson Humphrey acted as co-manager for the offering.

Deciphera intends to use the net proceeds from the offering to fund general corporate purposes, which may include research and development and clinical development costs to support the advancement of its drug candidates, including the continued growth of its commercial and medical affairs capabilities to support its transition from a development-stage company toward a commercial-stage company; the conduct of clinical trials and preclinical research and development activities; working capital; capital expenditures; general and administrative expenses; and other general corporate purposes.

You May Also Be Interested In

• Csquare launches IPO targeting up to $1.55B raise on NYSE
• Aethlon Medical prices $4M follow-on stock offering at $0.71 per share
• Evercore hires J.P. Morgan healthcare M&A co-head as senior MD